Cited by 205Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular HealthLipid metabolism and disorders

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes

Krentz, Andrew J·2003·Diabetes Obesity and Metabolism

DOI 10.1046/j.1462-8902.2003.0310.x

Open this paper in CoChat — free account

Abstract

Dyslipidaemia is common in patients with Type 2 diabetes and is held to be responsible for considerable CVD-related morbidity and mortality. Patients with Type 2 diabetes are at high risk from complications associated with atherosclerosis and should therefore receive preventive interventions. At the level of the adipocyte, impaired insulin action leads to increased rates of intracellular hydrolysis of triglycerides with the release of NEFA. The rise in NEFA provides substrate for the liver that, in the presence of impaired insulin action and relative insulin deficiency, is associated with complex alterations in plasma lipids: * Plasma VLDL levels are raised. (i). Increased VLDL levels are associated with post-prandial hyperlipidaemia that is compounded by impaired LPL activity. The latter may be independently associated with CAD. (ii). Remnant particles can deliver more cholesterol to macrophages than LDL-C particles. Thrombogenic alterations in the coagulation system also ensue from hypertriglyceridaemia. * Plasma HDL-C levels are reduced. (i). The reduction in cardioprotective HDL-C means a reduction of cholesterol efflux from the tissues--the first step in reverse cholesterol transport to the liver from peripheral tissues. (ii). The antioxidant and antiatherogenic activities of HDL-C are reduced when circulating levels are low. * LDL-C particles become small and dense. Small, dense LDL-C particles are held to be more atherogenic than their larger, buoyant counterparts because they (a) are more liable to oxidation and (b) may more readily adhere to and subsequently invade the arterial wall. The atherogenicity of LDL-C may also be enhanced by nonenzymatic glycation. Metabolic and lipid abnormalities can often be improved with lifestyle changes, including dietary modification, weight loss, smoking cessation and increased exercise. Although attainment of better glycaemic control may improve diabetic dyslipidaemia, pharmacological intervention is usually required. Several large-scale clinical trials, including 4S and more recently HPS, have clearly demonstrated the benefits of statins in reducing cardiovascular events. By virtue of their high absolute risk of CVD, many patients with Type 2 diabetes may achieve a greater risk reduction than their non-diabetic counterparts. For example, in 4S there was a 43% reduction in total mortality risk among patients with diabetes compared with 29% for non-diabetics and a reduced risk of MI by 55% vs. 32% for diabetic and non-diabetics, respectively. In the diabetic subgroup in HPS, there were reductions of approximately 25-30% in the risk of first major vascular events. More recently, the lipid-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) was halted early because of a significant reduction in cardiovascular events compared with placebo. Surprisingly an analysis of subgroups failed to show significance among the diabetic population, although the sample size, shortened follow-up period and higher drop-in statin use among diabetics on placebo may have affected results. The Collaborative Atorvastatin Diabetes Study (CARDS), involving 2800 patients with Type 2 diabetes, was halted 2 years early in June 2003 because patients allocated atorvastatin had significant reductions in MI, stroke and surgical procedures compared with those receiving placebo. The UKPDS demonstrated that the appearance and progression of certain microvascular complications of Type 2 diabetes could be reduced by treatment directed at hyperglycaemia and hypertension. In addition, correction of dyslipidaemia in patients with diabetes is important in reducing the high toll from macrovascular disease. The subjects in the HPS had similar lipid profiles to the participants in UKPDS, suggesting that additional benefit would accrue from a therapeutic assault on the main cardiovascular risk factors simultaneously. We now have firm evidence that appropriate use of statins in patients with Type 2 diabetes can significantly reduce cardiovascular morbidity and mortality.

Integrity signals

Registry

Crossref · 10.1046/j.1462-8902.2003.0310.x

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
(1998) · BMJ · doi:10.1136/bmj.317.7160.703 · Cited by 6,683
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876

Show all 56 references

Research works printed but not linked: 6

10.1007/BF02369347 · DOI
Miller M, 1998, Is hypertriglyceridaemia an independent risk factor for coronary heart disease?, European Heart J, H18
Durrington PN, 2002, Hyperlipidaemia
National Institute for Clinical Excellence., 2002, Management of Type 2 Diabetes: Management of Blood Pressure and Blood Lipids (Inherited Clinical Guideline H).
Wood D, 1998, Joint British recommendations on prevention of coronary heart disease in clinical practice, Heart, 80, S1
Pyorala K, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease, Diabetes Care, 1997, 614

Sorted by citations

Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell-Jones, D. L., & Khan, R. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 569
Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans
Eleazu, C. O., Eleazu, K. C., Chukwuma, S., & Udeme, N. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-60 · Cited by 461
“This causes irreversible O-glycosylation of intracellular proteins resulting in β-cell apoptosis [36,37].”
Background
Berries: emerging impact on cardiovascular health
Basu, A., Rhone, M., & Lyons, T. J. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00273.x · Cited by 462
Hyperglycemia and Glycation in Diabetic Complications
Nègre‐Salvayre, A., Salvayre, R., Augè, N., Pamplona, R., & Portero‐Otín, M. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2484 · Cited by 426
“The glycation of apoA-1 results in a progressive decrease in its antiatherogenic properties, particularly its ability to proceed to normal cholesterol reverse transport to the liver (168, 171).”
Effects of a cinnamon extract on plasma glucose, HbA1c, and serum lipids in diabetes mellitus type 2
Mang, B., Wolters, M., Schmitt, B., Kelb, K., Lichtinghagen, R., Stichtenoth, D. O., & Hahn, A. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01629.x · Cited by 354
Lipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354
“There seems to be a gradual shift to the uremic lipid profile as kidney function deteriorates (19,20), which is further modified by concurrent illnesses such as diabetes (21) and nephrotic syndrome (22).”
Background
Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages
Rosenblat, M., Hayek, T., & Aviram, M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.09.006 · Cited by 319
“Diabetic patients versus control healthy subjects have significant high serum triglyceride levels and low HDLcholesterol levels, as previously shown [ 35 ].”
Result
Evidence-Based Protocol for Diabetic Foot Ulcers
Brem, H., Sheehan, P., Rosenberg, H. J., Schneider, J. S., & Boulton, A. J. M. (2006) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000225459.93750.29 · Cited by 274
Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease
Southerland, J. H., Taylor, G. W., MOSS, K. L., Beck, J. D., & Offenbacher, S. (2006) · Periodontology 2000 · doi:10.1111/j.1600-0757.2005.00138.x · Cited by 209
Hyperlipidemia: a new therapeutic target for diabetic neuropathy
Vincent, A. M., Hinder, L. M., Pop‐Busui, R., & Feldman, E. L. (2009) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2009.00237.x · Cited by 183
“more prone to oxidation than smaller, high-density particles (Krentz, 2003).”
Background
Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications
Krentz, A. J., Clough, G. F., & Byrne, C. D. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00670.x · Cited by 171
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s61438 · Cited by 171
Identification of the Oxidized Low-Density Lipoprotein Scavenger Receptor CD36 in Plasma
Handberg, A., Levin, K., Højlund, K., & Beck‐Nielsen, H. (2006) · Circulation · doi:10.1161/circulationaha.106.626135 · Cited by 167
Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes
Shakeri, H., Hadaegh, H., Abedi, F., Tajabadi‐Ebrahimi, M., Mazroii, N., Ghandi, Y., & Asemi, Z. (2014) · Lipids · doi:10.1007/s11745-014-3901-z · Cited by 145
“Patients with T2DM are susceptible to metabolic complications and dyslipidemia [5].”
Background
Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury
Zhang, Y., Ma, K. L., Ruan, X. Z., & Liu, B. C. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14027 · Cited by 143
“Dyslipidaemia is more atherogenic in diabetic patients than in non-diabetic patients[74].”
Background
Treatment of dyslipidemia in patients with type 2 diabetes
Vijayaraghavan, K. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-144 · Cited by 139
“Abbreviations ACC: American College of Cardiology; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADA: American Diabetes Association; Apo: apolipoprotein; ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes TrialLipid-Lowering Arm; ASPEN: Atorvastatin Study for Prevention of coronary heart disease Endpoints in…”
BackgroundInfluential
Effects of Daily Consumption of Synbiotic Bread on Insulin Metabolism and Serum High-Sensitivity C-Reactive Protein among Diabetic Patients: A Double-Blind, Randomized, Controlled Clinical Trial
Tajadadi-Ebrahimi, M., Bahmani, F., Shakeri, H., Hadaegh, H., Hijijafari, M., Abedi, F., & Asemi, Z. (2014) · Annals of Nutrition and Metabolism · doi:10.1159/000365153 · Cited by 125
Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community‐dwelling men
Parsons, J. K., Bergstrom, J., & Barrett-Connor, E. L. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07332.x · Cited by 104
Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats
Roghani, M., & Baluchnejadmojarad, T. (2009) · Pathophysiology · doi:10.1016/j.pathophys.2009.07.004 · Cited by 98
Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice
Srivastava, R. A. K., Jahagirdar, R., Azhar, S., Sharma, S., & Bisgaier, C. L. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-9053-y · Cited by 95
“Insulin resistance is a fundamental aspect of the etiology of Type 2 diabetes and is linked to several metabolic abnormalities [10, 11].”
Background
RETRACTED ARTICLE: The Consumption of Synbiotic Bread Containing Lactobacillus sporogenes and Inulin Affects Nitric Oxide and Malondialdehyde in Patients with Type 2 Diabetes Mellitus: Randomized, Double-Blind, Placebo-Controlled Trial
Bahmani, F., Tajadadi-Ebrahimi, M., Kolahdooz, F., Mazouchi, M., Hadaegh, H., Jamal, A.-S., Mazroii, N., Asemi, S., & Asemi, Z. (2015) · Journal of the American College of Nutrition · doi:10.1080/07315724.2015.1032443 · Cited by 92
“T Patients with T2DM are susceptible to metabolic complications including dyslipidemia, increased inﬂammatory markers [28], oxidative stress, and hypertension [3].”
Retracted
RETRACTED ARTICLE:Paederia foetida Linn. leaf extract: an antihyperlipidemic, antihyperglycaemic and antioxidant activity
Kumar, V., Anwar, F., Ahmed, D., Verma, A., Ahmed, A., Damanhouri, Z. A., Mishra, V., Ramteke, P. W., Bhatt, P. C., & Mujeeb, M. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-76 · Cited by 91
Retracted
Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic (nSTZ) rats
Ghule, A. E., Jadhav, S. S., & Bodhankar, S. L. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.10.004 · Cited by 82
Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus
Woodman, R. J., Chew, G. T., & Watts, G. F. (2005) · Drugs · doi:10.2165/00003495-200565010-00003 · Cited by 83
Type 2 Diabetes Is Associated with Reduced ATP-Binding Cassette Transporter A1 Gene Expression, Protein and Function
Patel, D., Albrecht, C., Pavitt, D. V., Paul, V., Pourreyron, C., Newman, S. P., Godsland, I. F., Valabhji, J., & Johnston, D. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022142 · Cited by 82
“[4] RCT is the process by which excess cholesterol is removed from the body.”
Background
Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes
Tankova, T., Chakarova, N., Atanassova, I., & Dakovska, L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.12.020 · Cited by 101
“This represents the typical lipid profile associated with diabetes, characterized by increased plasma triglyceride level, as well as reduced HDL cholesterol and an increased proportion of small, dense, cholesteryl ester-depleted LDL particles with relatively normal or only mildly elevated LDL cholesterol concentration…”
Background
Consumption of medium- and long-chain triacylglycerols decreases body fat and blood triglyceride in Chinese hypertriglyceridemic subjects
Xue, C., Liu, Y., Wang, J., Zhang, R., Zhang, Y., Zhang, J., Zhang, Y., Zheng, Z., Yu, X., Jing, H., et al. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2008.76 · Cited by 78
Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes
Peters, A. L. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.1.3 · Cited by 78
Antihyperglycemic and antioxidant effects of Solanum xanthocarpum leaves (field grown & in vitro raised) extracts on alloxan induced diabetic rats
Poongothai, K., Ponmurugan, P., Ahmed, K., Kumar, B. K., & Sheriff, S. O. (2011) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(11)60193-4 · Cited by 74
Foxa2 Activity Increases Plasma High Density Lipoprotein Levels by Regulating Apolipoprotein M
Wolfrum, C., Howell, J. J., Ndungo, E., & Stoffel, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801930200 · Cited by 74
The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats
Refaie, F. M., Esmat, A. Y., Gawad, S. M. A., Ibrahim, A. M., & Mohamed, M. A. (2005) · Lipids in Health and Disease · doi:10.1186/1476-511x-4-22 · Cited by 74
“These lipoprotein abnormalities are held to be responsible for considerable cardiovascular disease-related morbidity and mortality [5].”
Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
Berne, C., Siewert-Delle, A., & the URANUS study investigators (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-7 · Cited by 73
“Treatment of diabetic dyslipidaemia may also reduce the incidence of microvascular disease including nephropathy [33].”
Background
Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients
Bamosa, A. O., Kaatabi, H., Lebda, F., Elq, A. H. A., & Al‐Sultan, A. I. (2012) · Journal of Family and Community Medicine · doi:10.4103/2230-8229.102311 · Cited by 75
“Patients with type 2 DM have a complex alteration in plasma lipids characterized by elevated level of triglycerides (TG), decreased level of high-density lipoprotein cholesterol (HDL-c), and a preponderance of small dense lowdensity lipoprotein cholesterol (LDL-c).[1,2] The abnormalities in circulating lipids and lipo…”
Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients
Dave, J. A., Levitt, N. S., Ross, I. L., Lacerda, M., Maartens, G., & Blom, D. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151911 · Cited by 75
Ethnopharmacological, Phytochemical, Pharmacological, and Toxicological Review on Senna auriculata (L.) Roxb.: A Special Insight to Antidiabetic Property
Nille, G. C., Mishra, S. K., Chaudhary, A. K., & Reddy, K. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.647887 · Cited by 68
“Senna auriculata (L.) Roxb. is reported to play an important role in the activation of hexokinase in alloxan-induced diabetic rats which found resulted in increased glycolysis and glucose consumption for energy production (Krentz, 2003).”
Background
Cardiovascular Risk Factors and 5-Year Mortality in the Copenhagen Stroke Study
Kammersgaard, L. P., & Olsen, T. S. (2005) · Cerebrovascular Diseases · doi:10.1159/000090531 · Cited by 66
“Diabetes is a disease that continues to increase the risk for myocardial infarction, recurrent stroke, and disability, conditions that put together might clearly explain the increased mortality risk after stroke [”
Background
Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?
Fonseca, M. I. H., da Silva, I. T., & Ferreira, S. R. G. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0221-5 · Cited by 68
“Therefore, postmenopausal obese type 2 diabetic individuals are prone to a combination of disorders that markedly increases the risk of dying from cardiovascular events [141, 142].”
Background
Antihyperglycemic and Antihyperlipidemic Effects of Aqueous Extracts of Lannea edulis in Alloxan-Induced Diabetic Rats
Banda, M., Nyirenda, J., Muzandu, K. M., Sijumbila, G., & Mudenda, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01099 · Cited by 64
α-Mangostin Mediated Pharmacological Modulation of Hepatic Carbohydrate Metabolism in Diabetes Induced Wistar Rat
Kumar, V., Bhatt, P. C., Kaithwas, G., Rashid, M., Al-Abbasi, F. A., Khan, J. A., Anwar, F., & Verma, A. (2016) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1016/j.bjbas.2016.07.001 · Cited by 60
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
Majali, K. A., Cooper, M. B., Staels, B., Luc, G., Taskinen, M., & Betteridge, D. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0092-4 · Cited by 58
Effect of DHA-rich fish oil on PPARγ target genes related to lipid metabolism in type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial
Mansoori, A., Sotoudeh, G., Djalali, M., Eshraghian, M., Keramatipour, M., Nasli‐Esfahani, E., Shidfar, F., Alvandi, E., Toupchian, O., & Koohdani, F. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.007 · Cited by 57
“Therefore, impaired reverse cholesterol transport (RCT) has been implicated.(10) In RCT process, excess cholesterol is removed from peripheral cells, and returned to the liver for clearance into the bile and ultimately the feces.”
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia
Hogue, J., Lamarche, B., Deshaies, Y., Tremblay, A. J., Bergeron, J., Gagné, C., & Couture, P. (2008) · Metabolism · doi:10.1016/j.metabol.2007.09.008 · Cited by 57
The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism
Eleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
“Furthermore, triglyceride-rich LDL particles undergo size reduction through the action of LPL and HL resulting eventually in the formation of small and dense LDL particles [1, 6, 7, 16, 19].”
BackgroundInfluential
Antidiabetic activity of cycloart-23-ene-3β, 25-diol (B2) isolated from Pongamia pinnata (L. Pierre) in streptozotocin–nicotinamide induced diabetic mice
Badole, S. L., & Bodhankar, S. L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.01.019 · Cited by 55
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
Balakumar, P., Kadian, S., & Mahadevan, N. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.01.004 · Cited by 53
Hypoglycemic and hypolipidemic activities of aqueous extract of flowers from Nycantus arbor-tristis L. in male mice
Rangika, B. S., Dayananda, P. D., & Peiris, L. D. C. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0807-0 · Cited by 50
Vascular Disease in the Metabolic Syndrome: Do We Need to Target the Microcirculation to Treat Large Vessel Disease?
Krentz, A. J., Clough, G. F., & Byrne, C. D. (2009) · Journal of Vascular Research · doi:10.1159/000226220 · Cited by 52
“] in patients with type 2 diabetes treated with insulin. Lipid-Modifying Drugs Statins reduce inflammation and prevent cardiovascular events in patients with or without diabetes [ ,”
Background
p66Shc: A novel biomarker of tubular oxidative injury in patients with diabetic nephropathy
Xu, X., Zhu, X., Ma, M., Han, Y., Hu, C., Yuan, S., Yuan, Y., Xiao, L., Liu, F., Kanwar, Y. S., et al. (2016) · Scientific Reports · doi:10.1038/srep29302 · Cited by 48
Antioxidative characteristics of aqueous and ethanol extracts of glossy privet fruit
Wang, Z., Hsu, C., & Yin, M. (2008) · Food Chemistry · doi:10.1016/j.foodchem.2008.06.078 · Cited by 47
Therapeutic Efficacy of Nyctanthes arbor-tristis Flowers to Inhibit Proliferation of Acute and Chronic Primary Human Leukemia Cells, with Adipocyte Differentiation and in Silico Analysis of Interactions between Survivin Protein and Selected Secondary Metabolites
Heendeniya, S. N., Keerthirathna, L. R., Manawadu, C. K., Dissanayake, I. H., Ali, R., Mashhour, A., Alzahrani, H., Godakumbura, P. I., Boudjelal, M., & Peiris, L. D. C. (2020) · Biomolecules · doi:10.3390/biom10020165 · Cited by 47
“Thus, alterations in the serum lipid levels are apparent during diabetic conditions, resulting in an increased risk for coronary heart ailments [60].”
Background
Hypoglycemic and Hypolipidemic Effects of Polyphenols from Burs of Castanea mollissima Blume
Yin, P., Zhao, S., Chen, S., Liu, J., Shi, L., Wang, X., Liu, Y., & Ma, C. (2011) · Molecules · doi:10.3390/molecules16119764 · Cited by 46
“Usually, diabetes is associated with profound alternation in lipid and lipoprotein profiles as illustrated in this study and literature [20].”
Background
Prevalence of Diabetes and Its Determinants in the Young Adults Indian Population-Call for Yoga Intervention
Nagarathna, R., Bali, P., Anand, A., Srivastava, V., Patil, S. S., Sharma, G., Manasa, K., Pannu, V. S., Singh, A., & Nagendra, H. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.507064 · Cited by 55
Effect ofSalvia miltiorrhizaHydrophilic Extract on Antioxidant Enzymes in Diabetic Patients with Chronic Heart Disease: A Randomized Controlled Trial
Qian, Q., Qian, S., Fan, P., Huo, D., & Wang, S. (2011) · Phytotherapy Research · doi:10.1002/ptr.3513 · Cited by 44
“The effect of S. miltiorrhiza on blood lipid profile in diabetic patients with CHD Treatment with S. miltiorrhiza for 30 days and 60 days did not show significant differences in the circulatory concentration of total cholesterol, triglyceride, LDL cholesterol, HDL cholesterol, compared with baseline and placebo (Table…”
BackgroundInfluential
Serum lipid and hsCRP levels in prediabetes – impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
Chakarova, N. Y., Tankova, T. I., Atanassova, I., & Dakovska, L. N. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.04.005 · Cited by 44
“The characteristic changes in serum lipid profile determined by insulin resistance are predominantly elevated triglyceride levels, increased FFAs and decreased HDL-c, which are in fact the major differences found in the present study between IFG on one side and IGT and NDD on the other [25,26].”
Background
Antidiabetic activity of lipophilic (−)-epigallocatechin-3-gallate derivative under its role of α-glucosidase inhibition
Li, T., Liu, J., Zhang, X., & Ji, G. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.11.002 · Cited by 44
The Effects of Resveratrol Supplementation on Endothelial Function and Blood Pressures Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Akbari, M., Tamtaji, O. R., Lankarani, K. B., Tabrizi, R., Dadgostar, E., Kolahdooz, F., Jamilian, M., Mirzaei, H., & Asemi, Z. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00324-6 · Cited by 45
Microsomal Triglyceride Transfer Protein Gene Expression and ApoB Secretion Are Inhibited by Bitter Melon in HepG2 Cells
Nerurkar, P. V., Pearson, L. N., Efird, J. T., Adeli, K., Theriault, A., & Nerurkar, V. R. (2005) · Journal of Nutrition · doi:10.1093/jn/135.4.702 · Cited by 42
Hypoglycemic and hypolipidemic activity of aqueous leaf extract of Passiflora suberosa L
Sudasinghe, H. P., & Peiris, L. D. C. (2018) · PeerJ · doi:10.7717/peerj.4389 · Cited by 40
“Alteration in the serum lipid profile is evident in diabetes resulting in an increased risk for coronary heart diseases (Krentz, 2003).”
Background
Lipids in health and disease
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 41
Managing Dyslipidemia in Type 2 Diabetes
Nelson, A. J., Rochelau, S. K., & Nicholls, S. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.004 · Cited by 38
A genome scan for serum triglyceride in obese nuclear families
Li, W., Dong, C., Li, D., Garrigan, C., & Price, R. A. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400391-jlr200 · Cited by 36
Effects of ursolic acid on glucose metabolism, the polyol pathway and dyslipidemia in non-obese type 2 diabetic mice.
Lee, J., Lee, H.-I., Seo, K.-I., Cho, H. W., Kim, M., Park, E., & Lee, M. (2014) · PubMed · Cited by 35
Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome
Srisawasdi, P., Vanavanan, S., Rochanawutanon, M., Kruthkul, K., Kotani, K., & Kroll, M. H. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.01.011 · Cited by 33
Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome
Fukushima, Y., Hirayama, S., Ueno, T., Dohi, T., Miyazaki, T., Ohmura, H., Mokuno, H., Miyauchi, K., Miida, T., & Daida, H. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.021 · Cited by 32
Impact of Hyperlipidemia on Plasma Protein Binding and Hepatic Drug Transporter and Metabolic Enzyme Regulation in a Rat Model of Gestational Diabetes
Anger, G. J., & Piquette‐Miller, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165639 · Cited by 31
“Hyperlipidemia is a common comorbidity among patients with type 1 or 2 diabetes (Ginsberg, 1996; Betteridge, 2000; Krentz, 2003; Harris et al., 2005) and represents an alternative explanation for altered protein binding in diabetes (RuizCabello and Erill, 1984; de la Fuente et al., 2002).”
Background
Anethum graveolens supplementation improves insulin sensitivity and lipid abnormality in type 2 diabetic patients
Mobasseri, M., Payahoo, L., Ostadrahimi, A., Bishak, Y. K., Jafarabadi, M. A., & Mahluji, S. (2014) · Pharmaceutical Sciences · Cited by 31
Pathophysiology and Long‐Term Management of the Metabolic Syndrome
Pi-Sunyer, X. (2004) · Obesity Research · doi:10.1038/oby.2004.285 · Cited by 31
“Although the low-density lipoprotein cholesterol (LDL-C) may be normal or only slightly elevated, the LDL particles are smaller, denser, and more atherogenic (”
Background
Male Gender, Increased Blood Viscosity, Body Mass Index and Triglyceride Levels Are Independently Associated with Systemic Relative Hypertension in Sickle Cell Anemia
Lamarre, Y., Lalanne‐Mistrih, M., Romana, M., Lemonne, N., Mougenel, D., Xavier Waltz, A., Tressières, B., Etienne‐Julan, M., Tarer, V., Hardy‐Dessources, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066004 · Cited by 31
“High TG level, associated to low HDL-C level, has been demonstrated to have pro-atherogenic, pro-thrombotic and pro-oxidant effects in patients with type 2 diabetes or metabolic syndrome [34].”
Background
Oral l-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin–nicotinamide induced diabetic rats
Badole, S. L., Bagul, P. P., Mahamuni, S. P., Khose, R. D., Joshi, A. C., Jangam, G. B., Ghule, A. E., Raut, C. G., Khedkar, V. M., & Coutinho, E. C. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.02.006 · Cited by 29
Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM)
Raj, R., Bhatti, J. S., Badada, S. K., & Ramteke, P. W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2630 · Cited by 30
“Good cholesterols and highdensity lipoprotein (HDL) can transport LDL from the walls of blood vessels and prevent arthrosclerosis [44].”
Background
Targeting caveolin-3 for the treatment of diabetic cardiomyopathy
Murfitt, L., Whiteley, G., Iqbal, M. M., & Kitmitto, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.03.002 · Cited by 29
“atherogenic in the diabetic as they are more susceptible to oxidation and glycation, which leads to greater adherent properties and facilitates penetration into the vessel wall (Krentz, 2003).”
Background
Modulatory effect of dianthrone rich alcoholic flower extract of Cassia auriculata L. on experimental diabetes
Khader, S. Z. A., Ahmed, S. S. Z., Balasubramanian, S. K., Arunachalam, T. K., Geetha, K., Mahboob, M. R., Ponnusamy, P., & Ramesh, K. (2017) · Integrative Medicine Research · doi:10.1016/j.imr.2017.01.007 · Cited by 29
Atherosclerosis indexes and incident T2DM in middle-aged and older adults: evidence from a cohort study
Wu, X., Gao, Y., Wang, M., Peng, H., Zhang, D., Qin, B., Pan, L., & Zhu, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00992-4 · Cited by 28
“It is prevalent in patients with T2DM and is believed to be the major cause of considerable CVD-related morbidity and mortality [14, 15].”
Background
Immunoglobulin E and mast cell proteases are potential risk factors of impaired fasting glucose and impaired glucose tolerance in humans
Wang, Z., Zhang, H., Shen, X.-H., Jin, K.-L., Ye, G.-F., Qiu, W., Li, Q., Li, B., Zhang, Y., & Shi, G. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.732234 · Cited by 28
Markers of Cardiovascular Risk in Postmenopausal Women with Type 2 Diabetes Are Improved by the Daily Consumption of Almonds or Sunflower Kernels: A Feeding Study
Richmond, K., Williams, S., Mann, J. I., Brown, R. C., & Chisholm, A. W. (2012) · ISRN Nutrition · doi:10.5402/2013/626414 · Cited by 28
“Diet Baseline mean (SD) Final mean (SD) Difference (95% CI) 𝑃𝑃 value Total cholesterol (mmol/L) Almond 5.88 (0.66) 5.55 (0.65) −0.14 (−0.29, 0.01) 0.073 Sun�ower kernel 6.11 (0.68) 5.56 (0.59) HDL cholesterol (mmol/L) Almond 1.27 (0.32) 1.26 (0.31) −0.04 (−0.085, −0.001) 0.045 Sun�ower kernel 1.32 (0.33) 1.25 (0.31) T…”
BackgroundInfluential
Antihyperglycemic and antihyperlipidemic effect of Rumex patientia seed preparation in streptozotocin-diabetic rats
Sedaghat, R., Roghani, M., Ahmadi, M., & Ahmadi, F. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2010.03.001 · Cited by 28
Role of SN1 Lipases on Plasma Lipids in Metabolic Syndrome and Obesity
Miksztowicz, V., Schreier, L. E., McCoy, M., Lucero, D., Fassio, E., Billheimer, J. T., Rader, D. J., & Berg, G. A. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.303027 · Cited by 27
“Lower LPL activity has been associated with severe hypertriglyceridemia accompanied by low levels of high-density lipoprotein–cholesterol (HDL-C).(3,4) HL is involved in HDL metabolism as well as being responsible for the metabolism of apolipoprotein B–containing lipoproteins (especially intermediate-density lipoprote…”
Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety
Yadav, R., France, M. W., Younis, N., Hama, S., Ammori, B. J., Kwok, S., & Soran, H. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.690395 · Cited by 27
“The sdLDL is more susceptible to oxidation and glycation compared with more buoyant LDL; hence it is assumed to be more atherogenic [76-78].”
Background
LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?
Nesto, R. W. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.1.8 · Cited by 27
Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics
Highlander, P. D., & Shaw, G. P. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709354305 · Cited by 26
“These small LDL particles that occupy the vessel wall are easier to oxidize and extremely atherogenic [Koba et al. 2008; Hayashi et al. 2007; Krentz 2003; Goldberg 2001].”
Background
Attenuation of Some Metabolic Deteriorations Induced by Diabetes Mellitus Using Carnosine
Soliman, K., Mohamed, A. M., & Metwally, N. (2007) · Journal of Applied Sciences · doi:10.3923/jas.2007.2252.2260 · Cited by 26
Antidiabetic potential of α-amylase inhibitor from the seeds of Macrotyloma uniflorum in streptozotocin-nicotinamide-induced diabetic mice
Gupta, L. H., Badole, S. L., Bodhankar, S. L., & Sabharwal, S. G. (2010) · Pharmaceutical Biology · doi:10.3109/13880209.2010.507633 · Cited by 24
“Diabetes mellitus often involves abnormal lipid metabolism which causes complications in diabetic subjects (Krentz, 2003).”
Background
Lipid profile among diabetes patients in Gaborone, Botswana
Mengesha, A. Y. (2006) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2006.10872137 · Cited by 24
A Relationship Between Alzheimer's Disease and Type 2 Diabetes Mellitus Through the Measurement of Serum Amyloid-β Autoantibodies
Kim, I., Lee, J., Hong, H. J., Jung, E. S., Ku, Y. H., Jeong, I. K., Cho, Y. M., So, I., Park, K. S., & Mook‐Jung, I. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1332 · Cited by 23
“Height, weight, body mass index (BMI), waist, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose, HbA1c, total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), and creatinine of samples were determined (Table 1…”
BackgroundInfluential
Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome
The Study Investigators, Ansquer, J.-C., Bekaert, I., Guy, M., Markolf Hanefeld, E., & Simon, A. C. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256580 · Cited by 23
Chinese Hypertriglycerideamic Subjects of Different Ages Responded Differently to Consuming Oil with Medium- and Long-Chain Fatty Acids
Changyong, X. U. E., Liu, Y., Wang, J., Zheng, Z., Zhang, Y., Zhang, Y., Zhang, R., Yu, X., Hongjiang, J. I. N., Nosaka, N., et al. (2009) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.80827 · Cited by 22
Statins and Neuropathic Pain: A Narrative Review
Pergolizzi, J. V., Magnusson, P., LeQuang, J. A., Razmi, R., Zampogna, G., & Taylor, R. (2020) · Pain and Therapy · doi:10.1007/s40122-020-00153-9 · Cited by 22
“It is transported by LDLs to the tissues, which means that lower LDL levels (for instance, because of statin therapy) can lead to less a -to- copherol delivered to the tissues [76].”
Background
Mechanistic Connections between Glucose/Lipid Disturbances and Weight Gain induced by Antipsychotic Drugs
Dwyer, D. S., Donohoe, D. R., Lu, X., & Aamodt, E. J. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(04)65008-2 · Cited by 22
Association among Microalbuminuria and Oxidative Stress Biomarkers in Patients with Type 2 Diabetes
Vicentini, J. T., Valentini, J., Grotto, D., Paniz, C., Roehrs, M., Brucker, N., Charão, M. F., Moro, A. M., Tonello, R., Moreira, A. P., et al. (2011) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31820eea24 · Cited by 21
“Moreover, the altered concentrations of lipoproteins are also found in glomerulopathy or chronic renal failure.(33) Interestingly, in our study, we observed a linear relationship between LDL cholesterol and microalbuminuria.”
Background
Determinants of uncontrolled dyslipidaemia among adult type 2 diabetes in Malaysia: The Malaysian Diabetes Registry 2009
Chew, B., Ismail, M., Lee, P. Y., Taher, S. W., Haniff, J., Mustapha, F. I., & Bujang, M. A. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.017 · Cited by 21
“with diabetes mellitus by the sheer presence of hyperglycaemia [6].”
Background
C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register
Pikkemaat, M., Andersson, T., Melander, O., Chalmers, J. P., Rådholm, K., & Boström, K. B. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.014 · Cited by 20
Models for Changing Patient Behavior
Dunbar‐Jacob, J. M. (2007) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000277821.67053.f7 · Cited by 20
C‐peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register
Pikkemaat, M., Melander, O., Mölstad, S., Garberg, G., & Boström, K. B. (2014) · Diabetic Medicine · doi:10.1111/dme.12608 · Cited by 19
Effect of Concomitant Administration of L-Glutamine and Cycloart-23-ene-3β, 25-diol (B2) with Sitagliptin in GLP-1 (7–36) Amide Secretion, Biochemical and Oxidative Stress in Streptozotocin - Nicotinamide Induced Diabetic Sprague Dawley Rats
Badole, S. L., Chaudhari, S. M., Bagul, P. P., Mahamuni, S. P., Khose, R. D., Joshi, A. C., Raut, C. G., & Zanwar, A. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072817 · Cited by 19
Effective care of patients with type 2 diabetes and dyslipidemia: A nurse's perspective
Adiseshiah, M. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.017 · Cited by 19
The apolipoprotein A5 gene –1131T→C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients
Girona, J., Guardiola, M., Cabré, A., Manzanares, J. M., Heras, M., Ribalta, J., & Masana, L. (2008) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.110 · Cited by 18
Clinical research Gestational diabetes mellitus is associated with increased leukocyte peroxisome proliferator-activated receptor γ expression
Wójcik, M., Mac‐Marcjanek, K., Nadel, I., Woźniak, L. A., & Cypryk, K. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.47692 · Cited by 17
“Arch Med Sci 4, August / 2015 785 and excretion in the bile, is related, at least in part, to this abnormality [54].”
Background
Cycloart-23-ene-3β, 25-diol stimulates GLP-1 (7–36) amide secretion in streptozotocin–nicotinamide induced diabetic Sprague Dawley rats: A mechanistic approach
Badole, S. L., Mahamuni, S. P., Bagul, P. P., Khose, R. D., Joshi, A. C., Ghule, A. E., Bodhankar, S. L., Raut, C. G., Khedkar, V. M., Coutinho, E. C., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.002 · Cited by 17
“It often involved abnormal lipid metabolism which is metabolic disorder in diabetic complications (Bansal et al., 2012; Krentz, 2003).”
Background
Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients
Sindhu, S., Singh, H. K., Salman, M. T., Fatima, J., & Verma, V. K. (2011) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.85954 · Cited by 17
“[25] Small, dense LDL particles are considered more atherogenic than the larger, buoyant LDL particles because they are more readily oxidized and glycated, which make them more likely to invade the arterial wall.[26,27] This can initiate atherosclerosis or lead to increased migration and apoptosis of vascular smooth m…”
Background
Hyperglycemia accelerates ATP‐binding cassette transporter A1 degradation via an ERK‐dependent pathway in macrophages
Chang, Y., Sheu, W. H., Chien, Y. H., Tseng, P., Lee, W., & Chiang, A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24478 · Cited by 16

Authors: Krentz, A. J.
Affiliations: Southampton General Hospital (GB)
Corresponding author: Krentz, Andrew J
ORCID: Krentz, Andrew J
Venue: Diabetes Obesity and Metabolism
Publisher: Wiley
Published: 2003-10-22
Volume: 5
Issue: s1
Pages: S19-27
ISSN: 1462-8902 (ISSN-L)
1463-1326
DOI: 10.1046/j.1462-8902.2003.0310.x
OpenAlex: W2117545273
Cited by: 205
References: 56
Citations by year: 2025: 3 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 9 · 2016: 12 · 2015: 10 · 2014: 21 · 2013: 10 · 2012: 14
FWCI: 1.66
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetes Obesity and Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: type 2 diabetes, dyslipidemia, cardiovascular disease, atherosclerosis, hypertriglyceridemia, small dense LDL, HDL cholesterol, remnant lipoproteins, lipoprotein lipase, VLDL, glycation, statins, lifestyle modification, reverse cholesterol transport, coronary artery disease, thrombosis
MeSH terms: Coronary Artery Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hyperlipidemias, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Risk Factors, Hypertriglyceridemia, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks